Name : Human BTLA Protein
Product Source :
Recombinant Human BTLA Protein is expressed from HEK293 with hFc tag at the C-Terminus. It contains Lys31-Ser150.[Accession | Q7Z6A9-1]
Molecular Weight :
The protein has a predicted MW of 40.5 kDa. Due to glycosylation, the protein migrates to 60-70 kDa based on Tris-Bis PAGE result.
Endotoxin Level :
Less than 1EU per μg by the LAL method.
Purity :
> 95% as determined by Tris-Bis PAGE> 95% as determined by HPLC
Formulation :
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
Reconstitution :
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage and Stability :
-20 to -80°C for 12 months as supplied from date of receipt. -80°C for 3-6 months after reconstitution. 2-8°C for 2-7 days after reconstitution. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Product Concentration :
Tris-Bis PAGE Human BTLA on Tris-Bis PAGE under reduced condition. The purity is greater than 95%. SEC-HPLC The purity of Human BTLA is greater than 95% as determined by SEC-HPLC. ELISA Data Immobilized Human HVEM, His Tag at 2μg/ml (100μl/Well) on the plate. Dose response curve for Human BTLA, hFc Tag with the EC50 of 7.2ng/ml determined by ELISA (QC Test). ELISA Data Immobilized Human BTLA, hFc Tag at 0.2μg/ml (100μl/Well) on the plate. Dose response curve for Biotinylated Anti-BTLA Antibody, hFc Tag with the EC50 of 11.4ng/ml determined by ELISA.
Background :
B- and T-lymphocyte attenuator (BTLA; CD272) is a 35 kDa type I transmembrane glycoprotein in the CD28 family of T cell costimulatory molecules. BTLA is a inhibitory receptor on lymphocytes that negatively regulates antigen receptor signaling via PTPN6/SHP-1 and PTPN11/SHP-2. BTLA may interact in cis (on the same cell) or in trans (on other cells) with TNFRSF14.
References & Citations :
(1)Haymaker C L , Wu R C , Ritthipichai K , et al. BTLA marks a less-differentiated tumor-infiltrating lymphocyte subset in melanoma with enhanced survival properties[J]. OncoImmunology, 2015, 4(8):e1014246.
Related category websites: https://www.medchemexpress.com/recombinant-proteins.html
Popular product recommendations:
Thioredoxin/TXNsite
CD5L Proteincustom synthesis
Popular categories:
IL-36
GLP-1 Receptor